Home > Healthcare > Pharmaceuticals > Active Pharmaceutical Ingredients > Ursodeoxycholic Acid Market

Ursodeoxycholic Acid Market Trends

  • Report ID: GMI6838
  • Published Date: Oct 2023
  • Report Format: PDF

Ursodeoxycholic Acid Market Trends

The escalating prevalence of liver and gallbladder disorders is a major driver for the growth of the market. Conditions like primary biliary cirrhosis, non-alcoholic fatty liver disease (NAFLD), gallstones, cystic fibrosis of liver, and others are increasingly diagnosed worldwide. For instance, according to the article published in Journal of Cystic Fibrosis, in 2022, around 162,428 people are estimated to be living with CF all over the globe. Ursodeoxycholic acid (UDCA) has great potential as an effective cystic fibrosis therapeutics.


Also, UDCA is undergoing extensive research for potential applications in addressing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). For instance, in primary biliary cirrhosis, UDCA has been established as a standard treatment that can significantly slow disease progression. Additionally, UDCA is employed as a non-surgical option for certain gallstone types, as it aids in dissolving them. Thus, the continuous increase in the prevalence of liver and gallbladder disorders necessitates effective treatments, which in turn propels the demand for UDCA API-containing medications.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Ursodeoxycholic acid industry size reached USD 581.7 million in 2022 and is poised to reach USD 1.4 billion by 2032 attributed to the increasing prevalence of liver diseases, such as primary biliary cholangitis and gallstones.

Synthetic segment is expected to be worth USD 958.6 million by 2032 driven by widespread utilization in the pharmaceutical and medical fields for its multitude advantages.

North America ursodeoxycholic acid market accounted for USD 203.7 million in revenue in 2022 and is expected to expand at notable CAGR through 2032 owing to increasing application due to the elevated prevalence of liver and gallbladder ailments UDCA.

Some of the top ursodeoxycholic acid companies are Daewoong Bio, ICE S.p.a., Merck KGa, Glenmark Pharmaceuticals Ltd., Dipharma Francis S.r.l., IOL Chemicals and Pharmaceuticals, Kimia Biosciences Ltd., Cerata Pharmaceuticals, and Changde Yungang Biotechnology Co. Ltd.,

Ursodeoxycholic Acid Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 14
  • Tables & Figures: 294
  • Countries covered: 22
  • Pages: 172
 Download Free Sample